tetano
Editor, Senior Moderator
Int Immunopharmacol
. 2021 Sep 8;100:108108.
doi: 10.1016/j.intimp.2021.108108. Online ahead of print.
Immune response variables and viral mutations impact on COVID-19 reinfection and relapse
Sarvin Sanaie[SUP] 1 [/SUP], Elham Golipour[SUP] 2 [/SUP], Ali Shamekh[SUP] 3 [/SUP], Mohammad Reza Sadaie[SUP] 4 [/SUP], Ata Mahmoodpoor[SUP] 5 [/SUP], Mehdi Yousefi[SUP] 6 [/SUP]
Affiliations
Abstract
The possibility of human reinfection with SARS-CoV-2, the coronavirus responsible for COVID-19, has not previously been thoroughly investigated. Although it is generally believed that virus-specific antibodies protect against COVID-19 pathogenesis, their duration of function and temporal activity remain unknown. Contrary to media reports that people retain protective antibody responses for a few months, science does not exclude reinfection and disease relapse shortly after initiating all immune responses during the primary onset of COVID-19. Despite production of antiviral antibodies, activated CD4+/CD8+ lymphocytes, and long-lived memory B cells, susceptibility to reinfection in humans for extended periods cannot be precluded due to repeated exposures to coronavirus or potential reactivation of the virus due to incomplete virus clearance. However, the mechanism of reinfection remains unknown. The biological characteristics of SARS-CoV-2, such as emergence of multiple mutations in the virus RNA molecules, transmissibility, rates of infection, reactivation and reinfection, can all affect the trajectory of the virus spread. Innate and adaptive immune response variables, differences in underlying diseases, and comorbidities, particularly in high risk individuals, can influence the dynamics of the virus infection. In this article, immune parameters and viral mutations pertaining to reinfection and disease relapse are reviewed and scientific gaps are discussed.
Keywords: COVID-19; Cytokines; Mutation; Neutralizing antibodies; Reinfection; Virus life cycle.
. 2021 Sep 8;100:108108.
doi: 10.1016/j.intimp.2021.108108. Online ahead of print.
Immune response variables and viral mutations impact on COVID-19 reinfection and relapse
Sarvin Sanaie[SUP] 1 [/SUP], Elham Golipour[SUP] 2 [/SUP], Ali Shamekh[SUP] 3 [/SUP], Mohammad Reza Sadaie[SUP] 4 [/SUP], Ata Mahmoodpoor[SUP] 5 [/SUP], Mehdi Yousefi[SUP] 6 [/SUP]
Affiliations
- PMID: 34521025
- DOI: 10.1016/j.intimp.2021.108108
Abstract
The possibility of human reinfection with SARS-CoV-2, the coronavirus responsible for COVID-19, has not previously been thoroughly investigated. Although it is generally believed that virus-specific antibodies protect against COVID-19 pathogenesis, their duration of function and temporal activity remain unknown. Contrary to media reports that people retain protective antibody responses for a few months, science does not exclude reinfection and disease relapse shortly after initiating all immune responses during the primary onset of COVID-19. Despite production of antiviral antibodies, activated CD4+/CD8+ lymphocytes, and long-lived memory B cells, susceptibility to reinfection in humans for extended periods cannot be precluded due to repeated exposures to coronavirus or potential reactivation of the virus due to incomplete virus clearance. However, the mechanism of reinfection remains unknown. The biological characteristics of SARS-CoV-2, such as emergence of multiple mutations in the virus RNA molecules, transmissibility, rates of infection, reactivation and reinfection, can all affect the trajectory of the virus spread. Innate and adaptive immune response variables, differences in underlying diseases, and comorbidities, particularly in high risk individuals, can influence the dynamics of the virus infection. In this article, immune parameters and viral mutations pertaining to reinfection and disease relapse are reviewed and scientific gaps are discussed.
Keywords: COVID-19; Cytokines; Mutation; Neutralizing antibodies; Reinfection; Virus life cycle.